Medical workers collecting samples for COVID-19 at the centre set up for mediapersons in New Delhi | Representational image | Photo: Suraj Singh Bisht | ThePrint
Medical workers collecting samples for COVID-19 at the centre set up for mediapersons in New Delhi | Representational image | Photo: Suraj Singh Bisht | ThePrint
Text Size:

New Delhi: A combination of two low-cost, widely available hepatitis C drugs may reduce the risk of death among patients hospitalised with Covid-19 in Iran, scientists have said. 

The findings are based on three trials and were presented at the International Aids Society Covid-19 scientific conference this week. “One of these small trials was not randomised so the researchers… stress that the results should be seen as preliminary,” British daily The Telegraph said in a report on the presentation.

According to the scientists, 94 per cent of hospitalised Covid-19 patients who were given a combination of sofosbuvir and daclatasvir had reduced fevers and improved breathing, as opposed to 70 per cent of those who did not get this drug combination.

The death rate for the combination of drugs was 5 per cent, compared to 20 per cent for people on standard care, The Telegraph reported. Since the conference was a closed event, other details of the presentation — for example, the size of the study and the severity of Covid-19 in the participating subjects — were not immediately available.  

“We saw significantly faster rates of clinical recovery and hospital discharge for people taking the drug combination and we also saw faster rates of survival,” said Dr Andrew Hill of Liverpool University, who was one of the researchers. 

Several computational studies as well as laboratory experiments have earlier shown that hepatitis C drugs can interfere with the RdRp enzyme of the novel coronavirus, which helps it multiply. 

The new studies reportedly showed that daclatasvir was more effective of the two as it penetrates into the lungs where Covid-19 infection is often concentrated.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW


Also Read: Psoriasis injection ‘Itolizumab’ approved for Covid-19 treatment by India’s drug controller


Under further study

Five clinical trials to test the drug combination, both as a treatment and a preventive measure against Covid-19, have now been initiated in Iran, Brazil, Egypt and South Africa. 

“It will be 10 weeks before we know properly whether it’s worked,” Hill said. 

“Sofosbuvir plus daclatasvir already has a well-established safety profile in the treatment of hepatitis C. Worldwide millions of people have been cured using this treatment,” Thiago Souza, one of the researchers from Brazil, was quoted as saying by The Telegraph

According to a report by The Financial Times, however, a separate study that included scientists from the US pharma giant Gilead, showed that sofosbuvir, alongside other antivirals, had no effect on the new coronavirus at standard doses.

Gilead is the manufacturer of remdesivir, another antiviral drug that is currently authorised for emergency use on Covid-19 patients in the US and India.


Also Read: Coronavirus could become resistant to Covid drug remdesivir, study says


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here